Clinical Trials Logo

Pancreatic Cancer Stage III clinical trials

View clinical trials related to Pancreatic Cancer Stage III.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06388967 Recruiting - Pancreatic Cancer Clinical Trials

Pancreatic Cancer Detection Consortium

PCDC
Start date: March 15, 2023
Phase:
Study type: Observational

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

NCT ID: NCT04406831 Recruiting - Clinical trials for Pancreatic Neoplasms

The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer

Start date: April 2015
Phase:
Study type: Observational

Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. The investigators hypothesize that the detection of certain miRNAs present in the blood/serum of patients with pancreatic cancer may be important to the early diagnosis of the disease. Furthermore, the investigators hypothesize that miRNA detection in PC patients will yield prognostic information and help predict the response to treatment.

NCT ID: NCT03236883 Recruiting - Clinical trials for Pancreatic Cancer Stage IV

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer

HST
Start date: April 2016
Phase: Phase 1
Study type: Interventional

To evaluate the safety and efficacy of non-myeloablative hematopoietic stem cell transplantation in the treatment of pancreatic cancer.

NCT ID: NCT01065870 Recruiting - Clinical trials for Pancreatic Cancer Stage III

Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)

Start date: December 2009
Phase: Phase 2/Phase 3
Study type: Interventional

This study is for patients with locally advanced pancreatic cancer (cancer that involves the local blood vessels so it cannot be removed without cutting major blood vessels) that cannot be treated with surgery. The purpose of this study is to assess the safety and benefit of 6 three week cycles of chemotherapy treatment consisting of gemcitabine, capecitabine and docetaxel (also called 'GTX'). The patients fall into two groups. Group I are those with only venous involvement. Group II patients have arterial involvement and may also have venous involvement. If there is arterial involvement, GTX will be followed by 5 and 1/2 weeks of radiation therapy with gemcitabine and capecitabine. After the chemotherapy and radiation treatment, participants may be able to have surgery to remove any remaining pancreatic cancer.